Elizabeth A Mckenna

US Patent:

20140030194, Jan 30, 2014

Filed:

Jan 16, 2013

Appl. No.:

13/743194

Inventors:

Elizabeth McKenna - Houston TX, US

Assignee:

Labyrinth Bio, Inc. - Houston TX

International Classification:

A61K 35/74

US Classification:

424 48, 424780, 424 934, 424 9345, 424 9344, 424 9346

Abstract:

The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.

US Patent:

20190290703, Sep 26, 2019

Filed:

Oct 28, 2018

Appl. No.:

16/172825

Inventors:

- Houston TX, US
Elizabeth McKenna - Houston TX, US

International Classification:

A61K 35/74
A61K 35/742
A61K 38/48
A61K 35/744

Abstract:

The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.

US Patent:

20180369367, Dec 27, 2018

Filed:

Jan 4, 2018

Appl. No.:

15/862209

Inventors:

- HOUSTON TX, US
Elizabeth McKenna - Houston TX, US

International Classification:

A61K 39/39
A61K 45/06
A61K 35/74

Abstract:

The present invention relates to combination therapies for the treatment of a variety of disorders in mammals, including hepatic disorders and cancer. The combination of agents includes naturally-occurring (versus synthetic) oligonucleotides, particularly immunostimulatory oligodeoxynucleotides such as CpG ODNs, obtained from a natural source and one or more extracts from a Gram positive bacteria, such as spp.

US Patent:

20180064767, Mar 8, 2018

Filed:

Sep 13, 2017

Appl. No.:

15/703607

Inventors:

Elizabeth McKenna - Houston TX, US

International Classification:

C12N 1/06
A61K 38/48
C12N 1/20
G01N 33/88
A61K 9/20
A61K 9/68
A61K 9/00

Abstract:

Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents.

US Patent:

20180064768, Mar 8, 2018

Filed:

Sep 13, 2017

Appl. No.:

15/703608

Inventors:

Elizabeth McKenna - Houston TX, US

International Classification:

C12N 1/06
A61K 38/48
C12N 1/20
G01N 33/88
A61K 9/20
A61K 9/68
A61K 9/00

Abstract:

Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents.

US Patent:

20180064769, Mar 8, 2018

Filed:

Sep 13, 2017

Appl. No.:

15/703611

Inventors:

Elizabeth McKenna - Houston TX, US

International Classification:

C12N 1/06
A61K 38/48
C12N 1/20
G01N 33/88
A61K 9/20
A61K 9/68
A61K 9/00

Abstract:

Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents.

US Patent:

20170348358, Dec 7, 2017

Filed:

Jun 16, 2017

Appl. No.:

15/626055

Inventors:

- Houston TX, US
Elizabeth McKenna - Houston TX, US

International Classification:

A61K 35/74
A61K 35/742
A61K 38/48
A61K 35/744
A61K 9/00
A61K 9/68

Abstract:

The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.

US Patent:

20170266277, Sep 21, 2017

Filed:

Mar 6, 2015

Appl. No.:

14/640075

Inventors:

- HOUSTON TX, US
Elizabeth McKenna - Houston TX, US

Assignee:

Labyrinth Holdings, LLC - Houston TX

International Classification:

A61K 39/39
A61K 9/00
A61K 45/06

Abstract:

The present invention relates to combination therapies for the treatment of a variety of disorders in mammals, including hepatic disorders and cancer. The combination of agents includes naturally-occurring (versus synthetic) oligonucleotides, particularly immunostimulatory oligodeoxynucleotides such as CpG ODNs, obtained from a natural source and one or more extracts from a Gram positive bacteria, such as spp.